BioLineRx Ltd. (BLRX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about BioLineRx Ltd. (BLRX)
Company Performance

Current Price

as of Oct 15, 2024

$0.03

P/E Ratio

N/A

Market Cap

$40.54M

Description

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Metrics

Overview

  • HQModi'in, HM
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerBLRX
  • Price$0.033913-1.87%

Trading Information

  • Market Cap$40.54M
  • Float91.11%
  • Average Daily Volume (1m)836,847
  • Average Daily Volume (3m)733,639
  • EPS-$0.11

Company

  • Revenue$63.56M
  • Rev Growth (1yr)N/A
  • Net Income$1.80M
  • Gross Margin78.82%
  • EBITDA Margin-93.57%
  • EBITDA-$18.80M
  • EV$150.06M
  • EV/Revenue2.36
  • P/EN/A
  • P/S2.39
  • P/B2.89
Documents